SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Dighiero G. CLL biology and prognosis. Hematology Am Soc Hematol Educ Program 2005: 278284.
  • 2
    Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. IgHV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 18401847.
  • 3
    Montserrat E. New prognostic markers in CLL. Hematology Am Soc Hematol Educ Program 2006: 279284.
  • 4
    Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 16391647.
  • 5
    Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt LM, Oscier DG. ZAP- 70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105111.
  • 6
    Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. ZAP- 70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893901.
  • 7
    Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 2005; 90: 391399.
  • 8
    Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E. ZAP- 70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 17641775.
  • 9
    Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103: 12021210.
  • 10
    Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, Corcoran MM, Chapman RM, Thomas PW, Copplestone JA, Orchard JA, Hamblin TJ. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 11771184.
  • 11
    Shankey TV, Forman M, Scibelli P, Cobb J, Smith CM, Mills R, Holdaway K, Bernal-Hoyos E, Van Der Heiden M, Popma J, Keeney M. An optimized whole blood method for flow cytometric measurement of ZAP-70 protein expression in chronic lymphocytic leukemia. Cytometry B Clin Cytom B 2006; 70B: 259269.
  • 12
    Kern W, Dicker F, Schnittger S, Haferlach C, Haferlach T. Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia. Cytometry B Clin Cytom B 2009; 76B: 385393.
  • 13
    Gachard N, Salviat A, Boutet C, Arnoulet C, Durrieu F, Lenormand B, Leprêtre S, Olschwang S, Jardin F, Lafage-Pochitaloff M, Penther D, Sainty D, Reminieras L, Feuillard J, Béné MC. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. Haematologica 2008; 93: 215223.
  • 14
    Degheidy HA, Venzon DJ, Farooqui MZH, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE. Combined normal donor and CLL: Single tube ZAP-70 analysis. Cytometry B Clin Cytom B 2012; 82B: 6777.
  • 15
    Smolej L, Vroblova V, Motyckova M, Jankovicova K, Schmitzova D, Krejsek J, Maly J. Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells. Neoplasma 2011; 58: 140145.
  • 16
    Rossi FM, Del Principe MI, Rossi D, Irno Consalvo M, Luciano F, Zucchetto A, Bulian P, Bomben R, Dal Bo M, Fangazio M, Benedetti D, Degan M, Gaidano G, Del Poeta G, Gattei V. Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: Mean fluorescence intensity T/B ratio versus percentage of positive cells. J Transl Med 2010; 8: 23.
  • 17
    Marquez M-E, Deglesne P-A, Suarez G, Romano E. MFI ratio estimation of ZAP-70 in B-CLL by flow cytometry can be improved by considering the isotype-matched antibody signal. Int J Lab Hematol 2011; 33: 194200.
  • 18
    Letestu R, Rawstron A, Ghia P, Villamor N, Boeckx N, Boettcher S, Buhl AM, Duerig J, Ibbotson R, Kroeber A, Langerak A, Le Garff-Tavernier M, Mockridge I, Morilla A, Padmore R, Rassenti L, Ritgen M, Shehata M, Smolewski P, Staib P, Ticchioni M, Walker C, Ajchenbaum-Cymbalista F. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. Cytometry B Clin Cytom B 2006; 70B: 309314.
  • 19
    Bakke AC, Purtzer Z, Leis J, Huang J. A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL). Cytometry B Clin Cytom B 2006; 70B: 227234.
  • 20
    Zucchetto A, Bomben R, Bo MD, Nanni P, Bulian P, Rossi FM, Del Principe MI, Santini S, Del Poeta G, Degan M, Gattei V. ZAP- 70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations. Cytometry B Clin Cytom B 2006; 70B: 284292.
  • 21
    Herishanu Y, Kay S, Rogowski O, Pick M, Naparstek E, Deutsch VR, Polliack A. T-cell ZAP-70 overexpression in chronic lymphocytic leukemia (CLL) correlates with CLL cell ZAP-70 levels, clinical stage and disease progression. Leukemia 2005; 19: 12891291.
  • 22
    Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. Int Soc Hematotherapy Graft Eng Cytometry 1998; 34: 6170.
  • 23
    Shankey TV, Forman M, Scibelli P. Optimized whole-blood assay for measurement of ZAP-70 protein expression. Curr Protoc Cytom 2007;Chapter 9:Unit9.22.
  • 24
    van Dongen JJM, Langerak AW, Brüggemann M, Evans PAS, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, García-Sanz R, van Krieken JHJM, Droese J, González D, Bastard C, White HE, Spaargaren M, González M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 22572317.
  • 25
    Peková S, Baran-Marszak F, Schwarz J, Matoska V. Mutated or non-mutated? Which database to choose when determining the IgVH hypermutation status in chronic lymphocytic leukemia? Haematologica 2006;91:ELT01.
  • 26
    Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 18481854.
  • 27
    Bayer J, Grunwald D, Lambert C, Mayol JF, Maynadié M. Thematic workshop on fluorescence compensation settings in multicolor flow cytometry. Cytometry B Clin Cytom B 2007; 72B: 813.
  • 28
    Béné MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, Lacombe F, Lemez P, Marinov I, Matutes E, Maynadié M, Oelschlagel U, Orfao A, Schabath R, Solenthaler M, Tschurtschenthaler G, Vladareanu AM, Zini G, Faure GC, Porwit A. Immunophenotyping of acute leukemia and lymphoproliferative disorders: A consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 2011; 25: 567574.
  • 29
    Shenkin M, Maiese R. Use of a blocking antibody method for the flow cytometric measurement of ZAP-70 in B-CLL. Cytometry B Clin Cytom B 2006; 70B: 251258.
  • 30
    Tobin G, Thunberg U, Johnson A, Thörn I, Söderberg O, Hultdin M, Botling J, Enblad G, Sällström J, Sundström C, Roos G, Rosenquist R. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99: 22622264.
  • 31
    Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stella S, Guida G, Michel A, Crespo M, Laoutaris N, Montserrat E, Anagnostopoulos A, Dighiero G, Fassas A, Caligaris-Cappio F, Davi F. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: The lesson of the IGHV3-21 gene. Blood 2005; 105: 16781685.
  • 32
    Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PAS, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956964.
  • 33
    Bekeredjian-Ding I, Doster A, Schiller M, Heyder P, Lorenz H-M, Schraven B, Bommhardt U, Heeg K. TLR9-activating DNA up-regulates ZAP70 via sustained PKB induction in IgM+ B cells. J Immunol 2008; 181: 82678277.
  • 34
    di Celle PF, Carbone A, Marchis D, Zhou D, Sozzani S, Zupo S, Pini M, Mantovani A, Foa R. Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin- 8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood 1994; 84: 220228.